Dr.
Ridker reports receiving grant support from AstraZeneca, Novartis,
Merck, Abbott, Roche, and Sanofi-Aventis; consulting fees or lecture
fees or both from AstraZeneca, Novartis, Merck, Merck–Schering-Plough,
Sanofi-Aventis, Isis, Dade Behring, and Vascular Biogenics; and is
listed as a coinventor on patents held by Brigham and Women's Hospital
that relate to the use of inflammatory biomarkers in cardiovascular
disease, including the use of high-sensitivity C-reactive protein in the
evaluation of patients' risk of cardiovascular disease. These patents
have been licensed to Dade Behring and AstraZeneca. Dr. Fonseca reports
receiving research grants, lecture fees, and consulting fees from
AstraZeneca, Pfizer, Schering-Plough, Sanofi-Aventis, and Merck; and Dr.
Genest, lecture fees from AstraZeneca, Schering-Plough,
Merck–Schering-Plough, Pfizer, Novartis, and Sanofi-Aventis and
consulting fees from AstraZeneca, Merck, Merck Frosst, Schering-Plough,
Pfizer, Novartis, Resverlogix, and Sanofi-Aventis. Dr. Gotto reports
receiving consulting fees from Dupont, Novartis, Aegerion, Arisaph,
Kowa, Merck, Merck–Schering-Plough, Pfizer, Genentech, Martek, and
Reliant; serving as an expert witness; and receiving publication
royalties. Dr. Kastelein reports receiving grant support from
AstraZeneca, Pfizer, Roche, Novartis, Merck, Merck–Schering-Plough,
Isis, Genzyme, and Sanofi-Aventis; lecture fees from AstraZeneca,
GlaxoSmithKline, Pfizer, Novartis, Merck–Schering-Plough, Roche, Isis,
and Boehringer Ingelheim; and consulting fees from AstraZeneca, Abbott,
Pfizer, Isis, Genzyme, Roche, Novartis, Merck, Merck–Schering-Plough,
and Sanofi-Aventis. Dr. Koenig reports receiving grant support from
AstraZeneca, Roche, Anthera, Dade Behring and GlaxoSmithKline; lecture
fees from AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, DiaDexus,
Roche, and Boehringer Ingelheim; and consulting fees from
GlaxoSmithKline, Medlogix, Anthera, and Roche. Dr. Libby reports
receiving lecture fees from Pfizer and lecture or consulting fees from
AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Pfizer,
Sanofi-Aventis, VIA Pharmaceuticals, Interleukin Genetics, Kowa Research
Institute, Novartis, and Merck–Schering-Plough. Dr. Lorenzatti reports
receiving grant support, lecture fees, and consulting fees from
AstraZeneca, Takeda, and Novartis; Dr. Nordestgaard, lecture fees from
AstraZeneca, Sanofi-Aventis, Pfizer, Boehringer Ingelheim, and Merck and
consulting fees from AstraZeneca and BG Medicine; Dr. Shepherd, lecture
fees from AstraZeneca, Pfizer, and Merck and consulting fees from
AstraZeneca, Merck, Roche, GlaxoSmithKline, Pfizer, Nicox, and Oxford
Biosciences; and Dr. Glynn, grant support from AstraZeneca and
Bristol-Myers Squibb. No other potential conflict of interest relevant
to this article was reported.
= = =
let's talk about Science now:
when the authors themselves explicitly declare these conflicts of interest, could such declarations raise any
doubts ?
Let's talk about the data, then.
In relation to CVDs, our team has been studying this field for 20 years.
Our views on omega-3 and statins are presented below in this review paper
and this book (chapter 6, on statins may be of some interest)
The Impact of Nutrition and Statins on Cardiovascular Diseases
To conclude: omega-3 and statins do not lower cardiovascular risk. The cholesterol hypothesis can not explain CVDs morbidity; inflammation is the killer, as explained few days ago...
COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation